wildpixel Checkpoint Therapeutics ( NASDAQ: CKPT ) and South Korea's GC Cell will collaborate on a combination treatment of the former's cosibelimab, an anti-PD-L1 antibody, and the latter's Immuncell-LC, a T-cell therapy. At the outset, the work will focus on in vitro studies to examine synergistic effects of the two treatments. Cosibelimab has an antibody-dependent cellular cytotoxicity mechanism of action and Immuncell-LC has an autologous Cytokine Induced Killer ("CIK") T-cell response.
Checkpoint noted that the combination "is expected to leverage immune system components more effectively in targeting and eliminating cancer cells." More on Checkpoint Therapeutics Checkpoint resubmits FDA application for cosibelimab Seeking Alpha’s Quant Rating on Checkpoint Therapeutics Historical earnings data for Checkpoint Therapeutics Financial information for Checkpoint Therapeutics.